Nkarta skyrockets following preliminary NKX101 and NKX019 data Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Twitter (TWTR) up 5% after Reuters reported the company is close to a deal to sell itself to Elon Musk for $54.20 per share in cash
- Nkarta (NKTX) up 100% after announcing preliminary Phase 1 data from independent dose finding studies of its two lead chimeric antigen receptor natural killer cell therapy candidates, NKX101 and NKX019, in two distinct groups of hematologic malignancies
- Penn National (PENN) up 2% after Morgan Stanley analyst Thomas Allen upgraded the stock to Overweight from Equal Weight
UP AFTER EARNINGS -
DOWN AFTER EARNINGS -
LOWER -
- Axsome Therapeutics (AXSM) down 25% after being informed by the FDA that chemistry, manufacturing, and controls issues identified during the FDA's review of the company's new drug application for its AXS-07 product candidate for the acute treatment of migraine are unresolved
- Verizon (VZ) down 2% after Goldman Sachs analyst Brett Feldman downgraded shares to Neutral from Buy
- Kellogg (K) down 2% after Deutsche Bank analyst Steve Powers downgraded the stock to Hold from Buy
- Deere (DE) down 3% after BofA analyst Ross Gilardi downgraded shares to Neutral from Buy
Symbols:
DE - $403.69 /
-20.615 (-4.86%)
TWTR NKTX PENN KO PHG AXSM VZ K Keywords: Fly Intel, Wall Street, Top Stories, Stocks